Nonprofit Patient Support and Peer Advocacy Groups for Myeloma in China
Public Interest Ecosystem · Vetting Advocacy Groups, Ethical Principles, and Digital Care Tools
Medical Disclaimer: The following content is compiled based on the latest authoritative guidelines at home and abroad. It is for reference only for patients and their families and cannot replace the professional medical advice of the attending physician. Please be sure to follow the doctor's advice for the treatment plan.
Core Conclusion
Facing a diagnosis of multiple myeloma or managing long-term relapses in China can easily create severe information overload and psychological isolation: relying on verified, zero-fee nonprofit advocacy networks and digital tracking tools is essential for maintaining clarity and avoiding predatory healthcare intermediaries.
1. Five Principles for Identifying Legitimate Patient Support in China
When searching for peer support groups or treatment information online, families must distinguish genuine patient-led communities from commercial operations:
Legitimate Nonprofit Patient Support
├── 100% Free: Never charges entrance, consulting, or matching fees
├── Evidence-Based: Grounded in CSCO, NCCN, and IMWG clinical guidelines
├── Official Registrations: References verifiable NMPA CDE trial codes (CTR-XXXX)
├── No Commercial Merchandising: Does not sell supplements, herbs, or unapproved devices
└── Physician-Centered: Emphasizes that clinical prescriptions must remain with treating hematologists
Any intermediary promising "guaranteed trial access" or "exclusive fast-track slots" for an upfront broker fee is operating outside Chinese healthcare regulations.
2. Charitable Assistance: Patient Assistance Programs (PAP)
For novel targeted drugs and monoclonal antibodies not fully covered by basic medical insurance, official charity donation programs exist in China:
- Authorized Foundation Administration: Programs are managed by registered charitable foundations (e.g., the Chinese Red Cross Foundation, Beijing New Sun Charity Foundation).
- Direct Application Process: Patients submit official hospital diagnostic reports, medical receipts, and household income certifications directly through the foundation's official platform.
- Zero Third-Party Intervention: No commercial agent can accelerate approvals. Legitimate foundations review applications strictly against clinical criteria and national poverty thresholds.
3. CMDN Digital Health and the "Myeloma Companion"
To empower patients across long-term chronic management, China Myeloma Digital Network provides free public tools:
- Independent Clinical Trial Directory: Direct, neutral matching against active CDE registrational studies across 31 Chinese provinces, filtered by line of therapy and genetic risk.
- "Myeloma Companion" (care.chinamyeloma.org): A lightweight digital care platform designed specifically for myeloma kinetics. Patients track M-protein spikes, immunoglobulins, and serum free light chains across treatment cycles.
- Structured Consultation Exports: Before clinic visits, patients can generate a one-page longitudinal PDF report, enabling hospital physicians to grasp multi-cycle disease response in seconds.
This guide is published by China Myeloma Digital Network (CMDN) as an open public-interest resource.
FAQs
- Do legitimate myeloma patient advocacy groups in China charge fees to patients?
- No. Genuine nonprofit patient organizations and peer support platforms in China never charge membership fees, group-entry fees, or clinical trial matching commissions. Any platform demanding upfront payment for doctor referrals or clinical trial access is an unregulated commercial intermediary.
- How can patients identify unauthorized medical brokers or fraudulent trial agencies?
- Verify five key rules: Legitimate groups never sell drugs, never promote health supplements, never charge placement commissions, reference verifiable NMPA CDE trial codes (CTR numbers), and never override a treating hematologist's medical authority. Immediately cease contact if a broker promises 'guaranteed cures' or requests private bank transfers.
- What is China Myeloma Digital Network (CMDN), and how does it operate?
- CMDN (ChinaMyeloma.org) is an independent, nonprofit digital health initiative established by caregivers and clinical researchers. CMDN sells no drugs or commercial products, receives no patient-referral kickbacks, and focuses entirely on evidence-based patient literacy, independent matching for active CDE clinical trials, and digital longitudinal disease tracking tools.
- How can financially constrained families in China access Patient Assistance Programs (PAP) for targeted drugs?
- Charitable drug access programs (PAP) in China are administered directly by state-certified public welfare foundations, such as the Chinese Red Cross Foundation or China Primary Health Care Foundation. Families apply directly through official foundation websites or WeChat portals with hospital receipts and diagnostic reports without paying third-party intermediaries.
- What digital tools are available in China for tracking myeloma lab trends over time?
- The 'Myeloma Companion' (care.chinamyeloma.org) is CMDN's secure digital health tool. It allows patients to log laboratory values (M-spike, serum free light chains, creatinine) over multi-cycle therapies, generating automated longitudinal trend graphs, early progression alerts, and structured physician consultation summaries before clinic visits.
Related reading
References used for this guide
Selected Multicenter Clinical Trials Monitored by CMDN
Explore selected active multicenter trials in China via CMDN non-profit navigation:
A Two-Stage, Randomized, Multicenter, Controlled, Open-Label, Phase III Study Comparing Iberdomide Maintenance Therapy with Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
This project is a Phase III clinical trial sponsored by Celgene (Bristol Myers Squibb/BMS), primarily targeting patients with newly diagnosed multiple myeloma (NDMM). Eligible patients must have received 3 to 6 cycles of prior induction therapy (including a proteasome inhibitor and an immunomodulatory drug), subsequently completed autologous stem cell transplantation (ASCT), and achieved at least a partial response (PR). Patients are randomized to receive maintenance therapy with either the investigational drug Iberdomide (a novel immunomodulatory agent administered for 21 days of each 28-day cycle) or the control drug lenalidomide (a conventional immunomodulatory agent administered continuously in 28-day cycles) until disease progression or unacceptable toxicity. The trial is conducted concurrently across 38 premier centers in China (including Hong Kong and Taiwan)—such as Peking University People's Hospital, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Zhejiang University School of Medicine, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, and Qilu Hospital of Shandong University—as well as leading international medical centers across 32 countries, including the United States, the United Kingdom, France, Japan, and Australia.
A Phase III, Randomized Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy (Including an Anti-CD38 Antibody and Lenalidomide)
This study aims to evaluate the efficacy and safety of JNJ-79635322 versus teclistamab in the treatment of multiple myeloma. The trial mainly enrolls adult participants with relapsed or refractory disease who have received 1 to 3 prior lines of anti-myeloma therapy (including an anti-CD38 antibody and lenalidomide). Eligible participants will be randomized to receive subcutaneous injections of JNJ-79635322 or teclistamab. This is an international multicenter study conducted simultaneously in multiple hospitals, including the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences.
A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone Versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
This project is a Phase III clinical trial sponsored by Hangzhou SJ Biosciences Co., Ltd. (Hangzhou Shangjian Biotechnology Co., Ltd.), primarily targeting participants with relapsed/refractory multiple myeloma (RRMM) who have received at least 1 prior line of therapy, have not previously received pomalidomide, and whose prior anti-CD38 antibody therapy was not determined to be refractory/ineffective. The treatment regimen utilizes an anti-CD38 monoclonal antibody (SG301 injection) combined with an immunomodulator (pomalidomide) and a glucocorticoid (dexamethasone), administered in 4-week (28-day) cycles until disease progression or intolerable toxicity. The trial is being conducted across a total of 78 top domestic hospitals in China, including the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences; The First Affiliated Hospital of Soochow University; Beijing Chaoyang Hospital, Capital Medical University; The Second Affiliated Hospital, Zhejiang University School of Medicine; and Sun Yat-sen University Cancer Center, among others.
A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC Versus DARZALEX FASPRO Combined with Lenalidomide-Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma
This randomized, double-blind Phase I study sponsored by Shanghai Henlius Biotech, Inc. enrolls adults with newly diagnosed multiple myeloma who are not eligible for stem cell transplantation. It compares the pharmacokinetics, safety, tolerability, and immunogenicity of subcutaneous HLX15-SC with DARZALEX FASPRO; both are administered with lenalidomide and dexamethasone (Rd). The study is being conducted at 66 sites in China, including Zhongshan Hospital, Fudan University and Peking University Third Hospital.
for their academic support:
for myeloma patients globally